Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: International IP
-
By Kevin E. Noonan — Four Congressman recently stepped into the crisis in world drug pricing, sending a letter to U.S. Trade Representative Susan Schwab last Thursday. The letter, signed by Congressman Charles Rangel (NY-15th Dist.), Congressman Rahm Emanuel (IL-5th Dist.), Congressman Sander Levin (MI-12th Dist.), and Congressman Chris Van Hollen (MD-8th Dist.),…
-
By Donald Zuhn — On April 25th, the State Intellectual Property Office (SIPO) of China announced the launch of an online patent database that allows for English language searches of the bibliographic data and abstracts of published Chinese patent documents. In particular, the database permits one to search the following fields of invention…
-
By Kevin E. Noonan — The U.S. Trade representative issued a "Special 301 Report" on Monday, pursuant to the provisions of the Trade Act of 1974. This report, on the state of intellectual property rights worldwide, identifies twelve countries on a "priority watch list" and promises consultations with Congress, affected industry groups, and…
-
By Kevin E. Noonan — Any hopes that Thailand would amend or overrule its policy of ignoring drug patent rights were dashed when the Thai government announced that it intended to maintain its extension of its compulsory licensing policy to four anti-cancer drugs: Novartis' Imatinib® and Letrozole®, Sanofi-Aventis' Docetaxel®, and Roche's Erlotinib®. The…
-
By Kevin E. Noonan — The latest skirmish in the struggle between innovator pharmaceutical companies (mostly in the Western world) and developing world populations is being played out in India. The outcome will depend on how the Delhi High Court interprets provisions of Indian patent law enacted to implement India’s compliance with provisions…
-
By Donald Zuhn — Yesterday, we counted down the first third of the top fifteen stories that were covered on Patent Docs in 2007 (see "Top Stories of 2007: #15 to #11"). Today, we count down stories #10 to #6, and tomorrow, we will count down the top five stories. In case you…
-
By Kevin E. Noonan — The effects of the global crisis in patented drug pricing were evident recently in two actions (or inactions) in the European Union. In the first, the Committee on International Trade of the European Parliament delayed voting on the Trade Related Intellectual Property Rights protocol promulgated by the World…
-
By Donald Zuhn — As we reported in May, the U.S. Trade Representative issued a report on the state of intellectual property rights worldwide, identifying Thailand as one of twelve countries on a "priority watch list." Thailand had been placed on the list as a result of its aggressive moves with respect to…
-
By Donald Zuhn — Last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) approved three new follow-on biologic drugs: Binocrit (Sandoz GmbH), Epoetin alfa Hexal (Hexal Biotech Forschungs GmbH), and Abseamed (Medice Arzneimittel Pütter GMBH & Co.). The approved biosimilars are generic versions of Johnson…
-
By Donald Zuhn — Last month, the European Medicines Agency (EMEA) released a paper entitled "Questions and Answers on biosimilar medicines (similar biological medicinal products)," in which the EMEA provided answers to a number of questions concerning the authorization of biosimilars. The European biosimilar regulatory pathway was established in 2004. In view of…
Patent Docs 